Ligand Pharmaceuticals Inc (LGND)
111.71
-3.74
(-3.24%)
USD |
NASDAQ |
Nov 15, 16:00
111.58
-0.13
(-0.12%)
After-Hours: 20:00
Ligand Pharmaceuticals Research and Development Expense (TTM): 22.49M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 22.49M |
| June 30, 2024 | 22.34M |
| March 31, 2024 | 23.84M |
| December 31, 2023 | 24.54M |
| September 30, 2023 | 28.25M |
| June 30, 2023 | 31.95M |
| March 31, 2023 | 33.57M |
| December 31, 2022 | 36.08M |
| September 30, 2022 | 8.221M |
| June 30, 2022 | 15.92M |
| March 31, 2022 | 23.41M |
| December 31, 2021 | 32.11M |
| September 30, 2021 | 53.80M |
| June 30, 2021 | 49.71M |
| March 31, 2021 | 46.49M |
| December 31, 2020 | 40.50M |
| September 30, 2020 | 56.14M |
| June 30, 2020 | 57.03M |
| March 31, 2020 | 56.51M |
| December 31, 2019 | 55.91M |
| September 30, 2019 | 46.08M |
| June 30, 2019 | 37.82M |
| March 31, 2019 | 31.75M |
| December 31, 2018 | 27.86M |
| September 30, 2018 | 27.66M |
| Date | Value |
|---|---|
| June 30, 2018 | 26.93M |
| March 31, 2018 | 25.62M |
| December 31, 2017 | 26.89M |
| September 30, 2017 | 24.66M |
| June 30, 2017 | 25.80M |
| March 31, 2017 | 25.89M |
| December 31, 2016 | 21.22M |
| September 30, 2016 | 17.09M |
| June 30, 2016 | 13.14M |
| March 31, 2016 | 11.64M |
| December 31, 2015 | 11.00M |
| September 30, 2015 | 9.634M |
| June 30, 2015 | 10.71M |
| March 31, 2015 | 9.983M |
| December 31, 2014 | 9.746M |
| September 30, 2014 | 11.22M |
| June 30, 2014 | 10.61M |
| March 31, 2014 | 9.941M |
| December 31, 2013 | 9.275M |
| September 30, 2013 | 9.376M |
| June 30, 2013 | 9.609M |
| March 31, 2013 | 10.44M |
| December 31, 2012 | 10.79M |
| September 30, 2012 | 10.91M |
| June 30, 2012 | 10.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
8.221M
Minimum
Sep 2022
57.03M
Maximum
Jun 2020
35.94M
Average
32.84M
Median
Research and Development Expense (TTM) Benchmarks
| Regeneron Pharmaceuticals Inc | 4.897B |
| Agios Pharmaceuticals Inc | 295.96M |
| ADMA Biologics Inc | 1.868M |
| Pieris Pharmaceuticals Inc | 16.02M |
| AnaptysBio Inc | 154.78M |